PharmExec Blog
Follow Us
RSS
Bookstore
Category Archives: Biotech
Pharma in the Dell: Working with Academia
How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai’s School of Medicine discussed ways to build a bridge across the valley of death, and the growing importance of data across all business areas.
Also posted in Deals, IP, Meetings, People, R&D, Strategy, Technology, leadership Tagged Celera, Data, Gilead, Intellectual property, Janssen, Mount Sinai School of Medicine, Pfizer Leave a comment
Pipeline Report Preview
Also posted in Advertising, Europe, FDA, Gene therapy, Global, IP, R&D, Regulatory, Strategy, Video Tagged business, Eli Lilly, Europe, FDA, Merck, Pfizer, pipeline, R&D, Strategy, United States Leave a comment
The Path of Least Resistance: Repositioned Drugs Surpass New Brands
It was in 1984 when FDA first added the 505(b)(2) pathway for drug approval, a hybrid between the accelerated pathway for generic drug applications, and the standard de novo NDA pathway for proprietary drugs. But in the past 6 years, approvals received through the 505(b)(2) pathway have consistently outnumbered de novo NDAs.
Also posted in FDA, IP, R&D, Regulatory, Strategy Leave a comment
Video: Think Small, Be Stealthy
Also posted in Global, Pharm Exec Magazine, R&D, Sales, Strategy, pricing Leave a comment
New York Pharma Forum: Together We Stand